Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
AstraZeneca
Scientific Title
A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab Versus Standard of Care Platinum-Based Chemotherapy as First Line Treatment in Patients with PD-L1-High Expression Advanced Non-Small-Cell Lung Cancer (NSCLC)